Results 61 to 70 of about 15,283 (290)

Huntingtin Aggregate‐Responsive Autophagy Gene Circuit Mitigates Disease Pathology in R6/2 Mice

open access: yesAdvanced Science, EarlyView.
CD98‐mediated receptor‐mediated transcytosis enables LIP‐CD98 nanocarriers to cross the blood–brain barrier and deliver ARAA to neurons. mHTT aggregates activate the 11G–NarX sensor, initiating Auto‐P and Trans‐P signaling through the VP48–NarL relay.
Jie Zhu   +8 more
wiley   +1 more source

Development and Characterization of a Primary Ciliated Porcine Airway Model for the Evaluation of In Vitro Mucociliary Clearance and Mucosal Drug Delivery

open access: yesPharmaceutics
Background/Objectives: In vitro models play a crucial role in preclinical respiratory research, enabling the testing and screening of mucosal formulations, dosage forms, and inhaled drugs.
Janik Martin   +12 more
doaj   +1 more source

CYD0281, a Bcl-2 BH4 domain antagonist, inhibits tumor angiogenesis and breast cancer tumor growth

open access: yesBMC Cancer, 2023
Background B-cell lymphoma 2 (Bcl-2) family proteins are key regulators of apoptosis, which possess four conserved Bcl-2 homologies (BH) domains. Among the BH domains, the BH3 domain is considered as a potent ‘death domain’ while the BH4 domain is ...
Yihua Lin   +15 more
doaj   +1 more source

Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) in Chinese patients often exhibits a mixed Type 1/2/3 inflammatory phenotype (63%), potentially impacting the efficacy of biologics targeting Type 2 inflammation. This prespecified subgroup analysis of WAYPOINT (NCT04851964) evaluated the efficacy and safety of tezepelumab in Chinese
Li Hu   +9 more
wiley   +1 more source

Safety and Biopharmaceutical Challenges of Excipients in Off-Label Pediatric Formulations

open access: yesInternational Journal of General Medicine, 2020
Anteneh Belayneh,1 Ebisa Tadese,2 Fantahun Molla2 1Department of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia; 2Department of Pharmaceutics, School of Pharmacy, College of Health Sciences, Mekelle University ...
Belayneh A, Tadese E, Molla F
doaj  

Developing Clinically Relevant Dissolution Specifications for Oral Drug Products—Industrial and Regulatory Perspectives

open access: yesPharmaceutics, 2019
A meeting that was organized by the Academy of Pharmaceutical Sciences Biopharmaceutics and Regulatory Sciences focus groups focused on the challenges of Developing Clinically Relevant Dissolution Specifications (CRDS) for Oral Drug Products.
Mark McAllister   +8 more
doaj   +1 more source

Correlations of mRNA Levels among Efflux Transporters, Transcriptional Regulators, and Scaffold Proteins in Non-Small-Cell Lung Cancer

open access: yesCanadian Journal of Infectious Diseases and Medical Microbiology, 2021
Multidrug resistance (MDR) due to enhanced drug efflux activity of tumor cells can severely impact the efficacy of antitumor therapies. We recently showed that increased activity of the efflux transporter P-glycoprotein (P-gp) associated with activation ...
Xieyi Zhang   +12 more
doaj   +1 more source

Non‐contrast CT Markers of Hematoma Expansion and Andexanet Response in Factor Xa Inhibitor‐Associated Intracerebral Hemorrhage: An Analysis from ANNEXa‐I Trial

open access: yesAnnals of Neurology, EarlyView.
In this post hoc analysis of the ANNEXa‐I trial (n = 434), we evaluated non‐contrast computed tomography (NCCT) markers of hematoma expansion (HE) in factor Xa inhibitor (FXai) –associated intracerebral hemorrhage (ICH). At least one NCCT marker was present in 72.1%, and HE (≥12.5 mL or ≥ 35% increase in hematoma volume) occurred in 31.8 ...
Koji Tanaka   +35 more
wiley   +1 more source

The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines

open access: yes, 2019
The recent impact of the Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS) on relevant scientific advancements is discussed.
Bergström, C.   +3 more
core   +2 more sources

Biological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome

open access: yesPharmaceutics
The discovery of new drugs offers valuable alternatives, particularly for treating diseases that are resistant to existing therapies or involving complex, multi-organ conditions such as metabolic syndrome. Although treatment algorithms are generally well
Wiktoria Górecka   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy